p16+ oropharyngeal squamous cell carcinoma

Outcomes for p16 positive, HPV negative oropharyngeal SCC are not significantly different from p16 positive, HPV positive tumors and are significantly better than for p16 negative tumors. (20588174)

These results suggest that p16 immunohistochemistry alone is the best test to use for risk stratification in oropharyngeal SCC.

Evolution

 Local metastasis
 Distant metastasis (DM) (24211084)

• With good loco-regional control, disease failure in p16-positive oropharyngeal squamous cell carcinoma (OPSCC) mainly results from distant metastasis (DM).
• In a study, the 2-year post-DM PFS in the p16-positive group was 20% (95% CI: 8-32.5%, p=0.003). (24211084)
• The 3-year post-DM disease-specific survival (DSS) estimate in the p16-positive patients was 16% (95% CI: 7-18%). (24211084)
• The DM pattern did not differ remarkably between p16-positive and negative OPSCC patients in our practice. (24211084)
• In p16-positive OPSCC with pulmonary oligometastatic disease, curative intent treatment and optimized locoregional control for the index primary prolonged survival. (24211084)

See also

 oropharyngeal squamous cell carcinoma

• HPV-associated oropharyngeal squamous cell carcinoma

Open references

 Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. Sinha P, Thorstad WT, Nussenbaum B, Haughey BH, Adkins DR, Kallogjeri D, Lewis JS Jr. Oral Oncol. 2014 Jan;50(1):45-51. doi : 10.1016/j.oraloncology.2013.10.007 PMID: 24211084 (Free)

References

 p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, El-Mofty SK. Am J Surg Pathol. 2010 Aug;34(8):1088-96. PMID: 20588174